Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma by Hough, R E et al.
Follicular lymphoma (FL) accounts for approximately 40% of all
non-Hodgkin’s lymphoma (NHL). It is an indolent disease with a
median survival of 7 to 9 years, but is currently incurable and the
majority of patients die of their lymphoma (Bastion et al, 1998).
Diffuse large B cell lymphoma (DLBL) constitutes a similar pro-
portion of all cases of NHL. Whilst characterized by an aggressive
clinical behaviour, durable remissions can be achieved in up to
50% of patients with combination chemotherapy and radiotherapy
(Armitage, 1993). Histological transformation to DLBL will occur
in 25–60% of cases of FL (Acker et al, 1983; Horning and 
Rosenberg, 1984). Progression to DLBL usually coincides with
more florid clinical disease which is refractory to treatment and
median survival following transformation is less than 12 months
(Bastion et al, 1998). 
Despite considerable recent advances in our understanding of
the cytogenetics and molecular genetics of NHL, the mechanisms
responsible for histological transformation and subsequent resist-
ant clinical behaviour remain poorly elucidated. Pathways involv-
ing the MYC oncogene (Lee et al, 1989; Yano et al, 1992) or p53
tumour suppressor gene (Lo Coco et al, 1993; Sander et al, 1993)
have been implicated. 
A clear understanding of the genetic basis for these events will
be central to the development of new therapeutic strategies to im-
prove the otherwise poor outcome for this group of patients. We
have used comparative genomic hybridization (CGH) to look for
novel areas of genomic copy number change in paired biopsies
from 24 patients before and after transformation from FL to DLBL
and in 18 patients with de novo DLBL. 
MATERIALS AND METHODS 
Patient selection 
24 patients with biopsy-proven FL at diagnosis and subsequent
transformation to DLBL and 18 patients with de novo DLBL were
identified using the regional clinical and pathological databases.
Paraffin-embedded tumour tissue from each biopsy was obtained
for all patients. The histological diagnoses were confirmed prior to
DNA extraction according to the REAL classification by the same
expert haematopathologist (JRG) (Harris et al, 1994). Cases of de
novo DLBL with remnants of possible FL were noted as these may
represent transformation from occult FL. Data regarding presenta-
tion, response to treatment, time to transformation and survival
were obtained by detailed review of the clinical records. 
DNA extraction 
Areas consisting of at least 50% tumour cells were identified by
immunocytochemistry using CD20, CD79a, CD43, CD3 and
CD45RO. These areas were microdissected from 6–10 serial tis-
sue sections (5 mm) from each biopsy. Genomic DNA was pre-
pared by enzymic digestion using the Qiagen tissue kit. DNA
quality was assessed using spectophotometry (Lambda Bio
UV/VIS spectrophotometer – Perkin Elmer). The mean of 2 read-
ings at wavelengths of 260 nm and 280 nm were recorded. An estim-
ate of purity was obtained from the ratio of readings at 260 nm 
and 280 nm (ratios of 1.7–1.9 indicated adequate DNA purity).
DNA concentration was calculated from the reading at 260 nm
(1OD = 50 mg ml21). DNA of sufficient quality could not be ob-
tained for 6 of the FL biopsies and 1 transformed DLBL biopsy.
Once extracted, sample identification was encrypted until comple-
tion of all analyses. 
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Comparative genomic hybridization 
Tumour DNA was compared to reference DNA for copy number
change using the technique described by Kallioniemi (Kallioniemi
et al, 1992, 1994). Equal amounts (1 mg) of tumour DNA and nor-
mal placental, same sex DNA were labelled with Spectrum Green
(Vysis) and Spectrum Red (Vysis) respectively by a standard nick
translation reaction to give probe fragment length of 300–3000 bp.
800 ng of each labelled DNA and 60 mg of human COT-1 DNA
(Gibco) were cohybridized to normal human metaphase chromo-
somes (Vysis) at 37˚C for 4 days. Chromosomes were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI) following
post-hybridization washes. 
Digital image analysis 
3 colour digital images were acquired using a KAF-1400 cooled
CCD camera (Photometrics) attached to an epifluorescence micro-
scope (Zeiss Axioskop). Dedicated software, QUIPS (Vysis), was
used to calculate the ratio of green (tumour DNA) to red (normal
DNA) fluorescence along the length of each chromosome. Mean
ratio profiles were calculated using 5 to 8 target metaphases for
each biopsy. Abnormalities at 1p32-ter, 16p, 19, 22 and Y were not
included as these areas have been found to be unreliable in CGH
analysis (Kallioniemi et al, 1994). 
Controls 
Ratio values of 1.2 and 0.8 were established as thresholds for gain
and loss respectively based on results from 3 controls used with
every experiment. These consisted of reference male DNA co-
hybridized with reference female DNA, normal female DNA 
micro-dissected and extracted from paraffin-embedded tonsil co-
hybridized with same sex reference DNA and a cell line (MPE
600, Vysis) with established amplifications and deletions against
normal opposite sex reference DNA. Ratio values exceeding 1.4
were defined as amplification events. 
Survival 
Survival curves were calculated using the method of Kaplan and
Meier. The statistical significance of differences observed was
determined using the log rank test. 
RESULTS 
Patients 
Paired FL and transformed DLBL biopsies were obtained for 24
(9 female, 15 male) patients. Biopsy material of de novo DLBL
was obtained for 18 (9 female, 9 male) patients. No previous
chemotherapy or radiotherapy had been administered prior to the
initial FL or de novo DLBL biopsies with the exception of two
patients; one had received radiotherapy and tamoxifen for carci-
noma of the breast and subsequently developed FL of the tonsil,
the second had achieved a complete remission with PACEBOM
chemotherapy for high-grade lymphoma but presented 8 months
later with FL. 
CGH data 
Copy number gains were seen more frequently than losses (Table
1). The FL biopsies demonstrated the fewest abnormalities. The
transformed DLBL had the most complex numerical abnormali-
ties. Figure 1 summarizes gains and losses according to histolog-
ical subtype; FL, DLBL following transformation and de novo
DLBL. A number of abnormalities were common to all 3 types
of biopsies (Table 2). Specific patterns of copy number change
were seen in the DLBL biopsies irrespective of its origin and
were never seen in FL cases (Table 3). A number of abnormali-
ties were only found in the transformed DLBL biopsies that were
neither present in the FL counterpart nor the de novo DLBL cas-
es (Table 4). Enh (12q12q14) was seen in 12 of the transformed
DLBL biopsies. This abnormality was also found in two de novo
DLBL patients; both had histological features suggestive of
transformation from an occult FL at histological review prior to
this study. One of these patients had a 2 year history of a lump in
the right groin and only sought a medical opinion as it suddenly
increased in size. The second patient had a clinical presentation
and course more typical of de novo DLBL. 
Table 1 CGH data summary 
Mean number of  FLa Transformed De novo All cases
abnormalities (range) DLBLb DLBLb
Gains 4.3 (1–9) 5.5 (1–14) 4.6 (1–9) 4.9 (1–14) 
Losses 1.2 (0–3) 3.0 (0–11) 2.0 (0–9) 2.2 (0–11) 
All events 5.6 (1–12) 8.5 (4–18) 6.6 (3–13) 7.0 (1–18) 
Chromosomes with gains 2.7 (1–4) 3.8 (1–10) 3.4 (1–8) 3.4 (1–10) 
Chromosomes with losses 1.2 (0–3) 2.7 (0–8) 2.0 (0–9) 2.0 (0–9) 
Chromosomes with events 3.8 (1–6) 6.3 (1–12) 5.2 (2–11) 5.2 (1–12) 
aFL = follicular lymphoma; bDLBL = diffuse large B cell lymphoma. 
Table 2 Abnormalities present in all three groups of biopsies 
Chromosome Band Number of FLa (n = 18) Number of transformed DLBLb (n = 23) Number of de novo DLBLb (n = 18) Total (n = 59)
3p dim 25–26 3 3 2 8 
4q enh 12–13 3 4 3 10 
5q enh 11.2–13 6 5 4 16 
7q enh 11.2 7 7 2 16 
8p dim 22–23 2 4 7 13 
10q dim 24–26 4 8 2 15 
11q enh 12–13 2 2 3 6 
Xp enh – 10 15 7 32 
Xq enh – 16 18 13 47 
aFL = follicular lymphoma; bDLBL = diffuse large B cell lymphoma.High level amplification was detected at 2p12–15 in 1 case,
3p12 (1 case), 11q12-13 (1 case), 12q12-13 (1 case), 12q13-21 
(1 case), 18p11.2 (1 case) and on the X chromosome (10 cases). 
Survival 
There was a trend towards poorer outcome in FL patients who had
gain at 12q12-14 in the transformed DLBL biopsy material; medi-
an survival from diagnosis and from transformation were 97
months and 23 months respectively in those who developed
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Table 3 Abnormalities present in both types of DLBL but never found in
FCL 
Chromosome Band Number of Number of  Total (n = 41)
transformed de novo 
DLBLa DLBLa
(n = 23) (n = 18)
1q dim 42–44 3 2 5 
2p enh 12–16 4 6 10 
12q enh 12–14 12 2 14 
15q dim 24–26 2 2 4 
Xq dim 27–28 3 2 5 
aDLBL = diffuse large B cell lymphoma. 
Table 4 Abnormalities only present in transformed DLBL 
Chromosome Band Number of transformed DLBLa (n = 23) 
2q enh 31–32 2 
5p dim 14–15.3 4 
6p enh 21.3–22 2 
7p enh 11.2–12 2 
8q dim 24.2–24.3 4 
17q enh 11.2–12 2 
aDLBL = diffuse large B cell lymphoma. 
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Figure 1 Ideograms showing cumulative gains and losses on CGH. (A) FL biopsies. (B) Transformed DLBL biopsies. (C) De novo DLBL biopsies. Copy 
number gains are represented by green lines to the right of each ideogram, whilst copy number losses are represented by red lines to the left. Amplification
events are identified by green lines of double thickness. enh(12q12-14) at transformation and 116 months and 35 months
respectively in those who did not. This difference was not statisti-
cally significant. 
DISCUSSION 
CGH has clearly demonstrated patterns of genomic gains and
losses, some of which are common to all groups, with others being
specific to histological subtype. The study of NHL by CGH to date
suggests that amplification and deletion of oncogenes and tumour
suppressor genes respectively may be more important in the path-
ogenesis of NHL than previously thought (Werner et al, 1997). 
Gains of chromosomal material (mean 4.9, range 1–14) were
observed more frequently than losses (mean 2.2, range 0–11), a
finding consistently demonstrated in all published series of CGH
and NHL. The most common abnormalities found, irrespective of
subtype, were gains on 4q, 5q, 7q, 11q and X and losses on 3p, 8p
and 10q. All subtypes of NHL have developed from the same
haematopoietic lineage and it would be reasonable to anticipate
certain similarities across the spectrum of this disease. Over-
representation on the X chromosome occurs in 21–50% of FL and
DLBL in reported CGH series (Bentz et al, 1996; Dierlamm et al,
1996; Joos et al, 1996; Monni et al, 1996; Avet-Loiseau et al,
1997) and was the most common aberration found in this study.
This correlates with well established cytogenetic data showing that
additional X chromosomes are the most frequent gains in NHL
(Fifth International Workshop on Chromosomes in Leukaemia-
Lymphoma, 1987; Offit et al, 1991; Hammond et al, 1992), with
possible oncogenic sites at Xp22 and Xq28 (Goyns et al, 1993).
Losses on 8p and 10q have also been reported in NHL (Goodacre
et al, 1994; Avet-Loiseau et al, 1996; Monni et al, 1996) and may
represent novel tumour suppressor gene sites. 
Comparison of FL and transformed DLBL paired biopsies from
the same patient provides a unique picture of the evolution of this
disease. Abnormalities found in the FL series were often present in
the transformed tissue, supporting the theory that the DLBL has
evolved directly from the initial FL clone. The transformed cases
were more complex, with a greater number of gains and losses
(Table 1). This may be a consequence of the accumulation of
genetic aberrations with repeated cell divisions (Yunis et al, 1987)
until a critical threshold is reached, beyond which the transformed
DLBL develops. However, certain abnormalities were repeatedly
found in the transformed tissue that were never present in the FL
counterpart, suggesting that specific, non-random events are 
necessary for transformation to occur. 
Gain on 2p and losses on 1q and 15q were present in both the de
novo and transformed DLBL biopsies but were never present in
FL. High level gain at 2p13-16 has been identified as a common
finding in high-grade NHL (Houldsworth et al, 1996; Joos et al,
1996; Werner et al, 1997) resulting from amplification of the REL
proto-oncogene at this site (Houldsworth et al, 1996; Joos et al,
1996). The specific abnormalities present in the DLBL tissue
irrespective of its origin may confer its histological phenotype. 
Over-representation on 2q, 6p, 7p and 17q and loss on 5p and 8q
were only ever found in the transformed DLBL cases. The histo-
logical appearance of de novo and transformed DLBL is usually
identical, but the clinical behaviour is quite different. It is possible
that the specific genetic abnormalities present in the transformed
cases reduce their susceptibility to cytotoxic drugs or ionizing 
radiation. 
Over-representation of 12q12-14 was found in 12 of 23 trans-
formed DLBL biopsies and was never present in the FL counter-
part. This gain was also found in 2 of the 18 de novo DLBL cases.
Both of these cases had been highlighted in the pathological review
at the beginning of the study as having histological features sug-
gestive of transformation from an occult FL. Gain at 12q12-14 is
one of the most common abnormalities found in the published
CGH data in high-grade NHL (Monni et al, 1996; Joos et al, 1996;
Rao et al, 1998). It was not stated in these studies, whether the cas-
es were de novo or transformed high-grade NHL. Emerging data
suggest that amplification of an oncogene at this site might also be
important in other human tumours (Elkahloun et al, 1996), includ-
ing sarcoma (Khatib et al, 1993), glioma (Reifenberger et al, 1994),
testicular germ cell tumour (Riou et al, 1995), prostatic carcinoma
(Sattler et al, 1999) and liposarcoma (Knuutila et al, 1998). The 12q
amplicon has been found to be highly complex, exhibiting discon-
tinuous regions of amplification (Wolf et al, 1997). There are a
number of candidate genes in this region which include MDM2,
CDK4, CDK2, GL1, ASA, and GAD153. MDM2 has been shown to
be over-expressed in some cases of high-grade NHL (Finnegan 
et al, 1994). It has a central role in the stabilization of p53 and could
theoretically reduce susceptibility to chemotherapy. More recently,
a gene encoding the human BAX inhibitor, BI1 has also been identi-
fied at this site. When over-expressed in mammalian cells, BI1 has
been shown to suppress BAX-induced apoptosis and can interact
with BCL2 which is known to be aberrantly expressed in nearly all
FCL (Xu and Reed, 1998). 
In contrast to others (Monni et al, 1997; Werner et al, 1997), we
found only one case in which there was low-level copy number
gain at 18q21, the site of the BCL-2 gene. The former group, in
particular, have frequently found high-level amplification at this
locus in DLBL. Werner and colleagues identified two such cases
in a series of 62 follicular and diffuse lymphomas (Werner et al,
1997). Such inconsistency may reflect the relatively smaller
number of cases in our study or population differences. At other
loci, our data are in complete agreement with these studies, with
high-level amplifications at 2p and on the X chromosome being
frequently observed abnormalities. 
If a specific genetic abnormality conferred drug resistance in
transformed DLBL, those patients found to have the abnormality
would be expected to have a poorer outcome. In this study, a trend
towards worse survival was observed in patients with gain at
12q12–14 present in the transformed DLBL DNA (23 months
compared with 35 months in those without the aberration). Pa-
tients with transformed DLBL have a very poor outcome because
the duration of response to currently available treatment modali-
ties is limited. If amplification of a gene contributing to this 
clinical behaviour could be identified, it would increase our under-
standing of the molecular mechanisms driving the transformation
event and might also provide a target for novel therapeutic 
strategies of the future. 
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